TickerTalks
Browse all tickers →
TickerTalks›$HCAT
HCHCAT

Health Catalyst, Inc.

$HCAT·$166M·Medical - Healthcare Information Services·Healthcare
$2.19-2.9%YTD-5.9%1Y-40.0%
Mentions · last 7 days
2026-07-13: 11 posts2026-07-14: 9 posts2026-07-15: 12 posts2026-07-16: 17 posts2026-07-17: 9 posts2026-07-18: 0 posts2026-07-19: 0 posts59+15%
Price updated 11m ago·X counts updated 21h ago
HCHCAT
$HCATHealth Catalyst, Inc.
$2.19-2.89%59 posts+15%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $HCAT, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storyWinding up for a moveAI verdict · as of 2026-07-20

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Health Catalyst is a $166M healthcare data-analytics microcap trading at 0.5x sales — Q1 was flat, and the board declassification failed.

Health Catalyst provides data-and-analytics software to healthcare providers, and the equity has drifted lower on a shrinking revenue base and unresolved governance issues: down 6% year to date, 40% over twelve months, and trading at just 0.47x trailing sales.

  • Q1 revenue of $70.8M was down 10.9% year on year with EPS of $0.02 beating a $0.01 estimate — the beat is small, and the year-on-year revenue trajectory (-11%, -6%, essentially flat) shows the platform hasn't returned to growth despite management restructuring.
  • Operating margin of -19%, ROIC of -19%, and debt-to-equity of 0.14 — the balance sheet is not the immediate constraint (debt is modest), but the return-on-capital deficit means every quarter of no-growth destroys value.
  • Board declassification failed at the recent annual meeting even after investors approved director slate and compensation — the governance framework the market wanted is not being installed, which limits the tools available for activist / strategic pressure.

August 6 Q2 earnings is the print: watch bookings and cross-sell to existing hospital-system customers, gross-margin trajectory, and any updated 2026 guide framework. A single quarter of positive revenue growth would validate the coiled-setup framing; another decline confirms the broken-story lens.

What to watch: Aug 6 Q2 earnings: bookings to hospital-system customers, gross-margin trajectory, and 2026 guide.

On the calendar: 2026-08-06

Read the AI verdict + X sentiment for $HCAT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Data and analytics platform for healthcare systems, integrating clinical and operational data for performance improvement.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Healthcare Information Services sits in its cycle right now — and what that implies for $HCAT.

Medical - Healthcare Information Services · Healthcare

No material change from last week — VEEV's 'agentic commercial' CRM framing converts AI from feature to platform pricing, while TEM's oncology AI platform and pharma data licensing confirm AI..

What this means for $HCAT

Partial — Data and analytics platform for healthcare systems, integrating clinical and operational data for performance improvement; partial earnings exposure to medical - healthcare information services demand dynamics through its product portfolio.

Industry benchmark

9-name peer basket
+53.7%YTD
+73.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-0.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-18.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-19.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-99.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
46.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 11, 2026$0.02$0.01+100.0%
Q4 2025Mar 12, 2026$0.08$0.09-11.1%
Q3 2025Nov 10, 2025$0.06$0.05+20.0%
Q2 2025Aug 7, 2025$0.04$0.03+33.3%
Next earningsThu, Aug 6·consensus EPS $0.02

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$70.8M-10.9%33.4%-9.5%$-1.53$13.6M
Q4 FY25$74.7M-6.2%52.7%4.4%$-1.28$9.6M
Q3 FY25$76.3M-0.0%49.5%-22.9%$-0.32$-5.3M
Q2 FY25$80.7M+6.3%47.4%-46.0%$-0.59$-8.8M

Forward consensus

3-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$263.2M$261.5M – $264.2M$0.04-$0.21 – $0.255
FY27$247.1M$233.3M – $272.3M$0.09-$0.32 – $0.515
FY28$247.1M$247.1M – $247.1M$0.03$0.02 – $0.032

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.41%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+30.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+10.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 61.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.575-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 24 other (15 inkinds · 9 awards) in window

See when $HCAT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13DActivist position (5%+)Jun 22SC 13D
AI summary

Schedule 13D filed by Palogic Value Management, LP reporting beneficial ownership of SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Health Catalyst, Inc. representing a 7% stake (4 shares), with investment intent. This SC 13D filing dated 2026-06-22 updates the holder's position and disclosed intentions.

SC 13D/AActivist amendmentJun 8SC 13D/A
AI summary

With filed Amendment No. 2 to Schedule 13D disclosing updated beneficial ownership in HCAT (HCAT). The filing covers approximately 3,285,690 shares of HCAT. The position is held for potential M&A activity. Schedule 13D amendments are required when a 5%-or-greater holder's ownership, intent, or plans change materially, providing transparency into concentrated positions that could influence corporate governance or trigger M&A activity.

8-KMaterial agreementJun 48-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

HCAT (HCAT) disclosed a material definitive agreement under Item 1.01, reporting a merger or acquisition transaction involving growth company as defined in Rule. The deal is valued at approximately $0. Details of the transaction terms, consideration structure, and closing conditions are set forth in the full 8-K filing. Definitive merger agreements are among the most material events a public company can disclose, triggering regulatory review and shareholder vote requirements.

3New insider — initial holdingsMay 43
AI summary

A new insider filed a Form 3 with the SEC, disclosing initial beneficial ownership of HCAT securities. This filing is required under Section 16(a) of the Securities Exchange Act within 10 days of becoming a reporting person (officer, director, or 10%+ holder). The filing reports 4 shares of common stock. Form 3 filings establish a baseline ownership record for subsequent Form 4 (changes) and Form 5 (annual) filings, providing transparency into insider positions at HCAT.

8-KOfficer or director changeApr 308-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

HCAT (HCAT) filed an 8-K under Item 5.02 disclosing a change in its executive leadership or board composition. The filing reports both a departure and an appointment in President. Individuals named in the filing include Employer Identification, South River. Leadership changes at the C-suite and board level are material events requiring 8-K disclosure within four business days, as they can affect company strategy, investor confidence, and operational continuity.

8-KOfficer or director changeApr 278-K — Item 5.02: Officer or director change · Item 8.01: Other event
AI summary

HCAT (HCAT) filed an 8-K under Item 5.02 disclosing a change in its executive leadership or board composition. The filing reports both a departure and an appointment in CTO. Individuals named in the filing include Employer Identification, South River. Leadership changes at the C-suite and board level are material events requiring 8-K disclosure within four business days, as they can affect company strategy, investor confidence, and operational continuity.

8-KOfficer or director changeApr 38-K — Item 5.02: Officer or director change
SC 13D/AActivist amendmentMar 13SC 13D/A
+ 15 other (2 proxys · 2 13Gs · 2 earnings 8-Ks · 2 10-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Health Catalyst Investors Approve Directors, Pay; Board Declassification Failsmarketbeat.com·4d agoHealth Catalyst to Participate in Upcoming Investor Conferenceglobenewswire.com·34d agoMed-Metrix Enters Into Definitive Agreement to Acquire Vitalware to Enhance Coding Accuracy and Net Revenue Yieldprnewswire.com·46d agoHealth Catalyst to Divest Vitalware for $147 Million, Accelerating Strategic Transformationglobenewswire.com·46d agoHealth Catalyst, Inc. (HCAT) Q1 2026 Earnings Call Transcriptseekingalpha.com·70d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Medical - Healthcare Information Services

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TEM$BTSG$VEEV$AMWL$TXG$PGNY$SLP$HNGE
Voices on X · last 7 days

No standout posts about $HCAT on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport